Inside the trichomes of every hemp and cannabis plant, a single compound is produced first. Cannabigerolic acid — CBGA — is the biochemical origin point from which the plant's entire cannabinoid profile develops. CBG, CBD, THC, CBC, and the dozens of minor cannabinoids that follow each begin as CBGA before enzymatic reactions convert them into their distinct final forms. Understanding CBGA is understanding where cannabinoids come from, why the plant's genetic variety shapes everything that comes after, and why growing a CBG-dominant variety means something at the molecular level that reaches all the way to the final preparation.

How the Plant Builds Its Cannabinoid Profile

CBGA is synthesised in hemp trichomes through the action of an enzyme called CBGA synthase, which combines olivetolic acid — derived from the plant's fatty acid metabolism — with geranyl pyrophosphate, a compound from the plant's terpenoid biosynthesis pathway. The resulting CBGA molecule is the universal precursor: every major phytocannabinoid downstream of this synthesis step begins here.

From CBGA, three primary enzymatic pathways branch. THCA synthase converts CBGA to THCA — the acid precursor of THC. CBDA synthase converts CBGA to CBDA — the acid precursor of CBD. CBCA synthase converts CBGA to CBCA — the acid precursor of CBC. Any CBGA not converted by these enzymes remains as CBGA, and over time or with heat exposure converts to CBG through decarboxylation.

The ratio of THCA synthase, CBDA synthase, and CBCA synthase activity in any given plant is primarily determined by genetics. A CBD-dominant hemp variety expresses high CBDA synthase activity — most CBGA is converted to CBDA, leaving little unconverted. A CBG-dominant variety expresses low or absent activity of all three converting enzymes — CBGA accumulates without being converted, and that unconverted CBGA is what eventually becomes CBG. This is the fundamental genetic explanation for why CBG-dominant varieties exist and why they are relatively uncommon: producing them requires selecting for the absence of the enzymatic activity that most plants express abundantly.

What the Research Shows About CBGA Itself

CBGA has received considerably less research attention than its downstream products CBD and THC, but the evidence that does exist points to biological activity that is independent of its precursor role. It is not pharmacologically inert.

The most established finding concerns CBGA's activity at peroxisome proliferator-activated receptors — specifically PPAR-alpha and PPAR-gamma. A 2019 study by Colasanti and colleagues examined CBGA's interaction with these nuclear receptors, which regulate fatty acid metabolism, inflammation, and glucose homeostasis. CBGA showed agonist activity at both PPAR subtypes in cell models, with effects on lipid accumulation and inflammatory signalling. PPAR-gamma is the same receptor target through which CBG has shown insulin sensitisation effects in preclinical models, suggesting that CBGA and its downstream product share a pharmacologically relevant mechanism.

A 2021 study by Bonn-Miller and colleagues examined several cannabinoids including CBGA for antiviral activity. CBGA and CBDA both demonstrated binding to the SARS-CoV-2 spike protein in cell-based assays, preventing cellular entry. This finding was widely reported in the popular press with significant overstatement — cell-based binding assays are very early-stage evidence, and no clinical data exists for CBGA or any cannabinoid as an antiviral agent. The finding is Tier 3 evidence at most, and is cited here only as illustration of the range of biological targets at which CBGA has shown preliminary activity, not as a basis for any therapeutic claim.

Antimicrobial activity has also been documented. The same 2008 Appendino study that examined CBG's antibacterial properties found CBGA active against MRSA strains, though at higher minimum inhibitory concentrations than CBG. Preliminary neuroprotective properties have been examined in models relevant to Huntington's disease, and anti-inflammatory activity has been documented through COX enzyme inhibition in in vitro models.

The honest assessment of CBGA's research profile is that it has documented biological activity across multiple receptor systems and biological targets, all at Tier 2 or Tier 3 evidence levels — preclinical models, cell assays, mechanistic studies. No human clinical trial has examined CBGA specifically. Its pharmacological profile is early but not empty, and it is a compound that warrants serious research attention that it has not yet fully received.

What a CBG-Dominant Variety Means at the Farm Level

Growing a CBG-dominant hemp variety is not simply a matter of selecting a different seed. The genetic trait that produces CBG dominance — low or absent converting enzyme activity — means the plant retains CBGA in its unconverted form through most of its growing cycle. That CBGA converts to CBG gradually over time and more completely with post-harvest processing, but a significant proportion of what is present in a fresh-harvested CBG-dominant plant is still CBGA rather than CBG.

A slow alcohol maceration at room temperature captures the plant material as it is at harvest — CBGA and CBG present together in the ratios the genetics and growing season produced. No heat is applied that would accelerate decarboxylation. No post-processing refinement separates one form from another. The preparation preserves the acid forms alongside the neutral forms, which means a CBG tincture prepared this way contains not only CBG but the CBGA from which it developed — a compound that has its own documented biological activity at overlapping receptor targets.

Whether the CBGA present in a slow-maceration CBG tincture contributes meaningfully to the preparation's biological profile has not been formally studied. It is a compound present in a concentration that is not negligible, at receptor targets that are not irrelevant, and that is preserved specifically because of the preparation method chosen. This is not a claim — it is a documented observation about what a slow-maceration whole-plant CBG preparation from a CBG-dominant variety actually contains, grounded in the biosynthesis and preparation chemistry described in this article and the articles it links to.

Harvest timing and CBGA

In a CBG-dominant variety, CBGA converts to CBG gradually as the plant matures through the growing season. Early harvest — before full maturity — produces a plant with higher residual CBGA and lower CBG. Late harvest produces more fully converted CBG with less remaining CBGA. Harvest timing is therefore a preparation decision as much as a growing decision — it shapes the acid-to-neutral ratio that reaches the final tincture. The full northern growing season in Minnesota, extending through September, allows the plant to reach optimal phytochemical maturity before harvest, producing a more fully developed CBG profile than a shorter season would permit.